PMID- 19083299
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20121002
LR  - 20081216
IS  - 1875-0834 (Electronic)
IS  - 1760-2734 (Linking)
VI  - 6
IP  - 1
DP  - 2004 May
TI  - Long-term tolerability of benazepril in dogs with congestive heart failure.
PG  - 7-13
LID - 10.1016/S1760-2734(06)70059-5 [doi]
AB  - OBJECTIVES: To test the tolerability of long-term administration of benazepril in 
      dogs with congestive heart failure (CHF). METHODS: The study was a prospective, 
      randomized, double-blinded, placebo-controlled clinical trial. A total of 162 
      dogs with New York Heart Association (NYHA) class II-IV heart failure caused by 
      chronic valvular disease (CVD) or dilated cardiomyopathy (DCM) were enrolled. 
      Benazepril (minimum dosage, 0.25 mg/kg) or placebo were administered orally once 
      daily for up to 34 months. In this paper, we report results of plasma alanine 
      aminotransferase (ALT), creatinine, potassium and urea. RESULTS: The two groups 
      were matched at baseline (p>/=0.18). Plasma creatinine concentrations were lower 
      during treatment with benazepril versus placebo for all dogs (p=0.14) and every 
      sub-group tested (NYHA II, III or IV; CVD; DCM; initial creatinine >124 mumol/L), 
      although statistical significance was not reached (p=0.14-0.6). However, 
      significantly (p=0.035) more cases of creatinine >124 mumol/L during treatment 
      occurred with placebo (47%) as compared to benazepril (30%). Plasma ALT and urea 
      values did not differ between groups for all dogs (p>0.5) or any sub-group 
      (p=0.23-1.0). Plasma potassium values did not differ between groups for all dogs 
      (p>0.5). Although differences approached statistical significance for potassium 
      in some sub-groups (p=0.07-0.1), there were no consistent differences between 
      groups. CONCLUSIONS: Benazepril was well tolerated during long-term therapy in 
      dogs with CHF and no specific precautions appear to be necessary regarding plasma 
      ALT, creatinine, potassium or urea. The possible action of benazepril in 
      improving renal function (evidenced via lower plasma creatinine) merits further 
      investigation.
CN  - BENCH (BENazepril in Canine Heart disease) Study Group
FAU - Pouchelon, Jean-Louis
AU  - Pouchelon JL
FAU - King, Jonathan
AU  - King J
FAU - Martignoni, Laure
AU  - Martignoni L
FAU - Chetboul, Valerie
AU  - Chetboul V
FAU - Lugardon, Beatrice
AU  - Lugardon B
FAU - Rousselot, Jean-Francois
AU  - Rousselot JF
FAU - Corlouer, Jean-Philippe
AU  - Corlouer JP
FAU - Bussadori, Claudio
AU  - Bussadori C
FAU - Piette, Marie-Helene
AU  - Piette MH
FAU - Brownlie, Serena
AU  - Brownlie S
FAU - Martel, Philippe
AU  - Martel P
FAU - Garcin, Jean-Pierre
AU  - Garcin JP
FAU - Hagen, Andreas
AU  - Hagen A
FAU - Amberger, Christophe
AU  - Amberger C
FAU - Martin, Michael
AU  - Martin M
FAU - Labadie, Fabrice
AU  - Labadie F
FAU - Collet, Michel
AU  - Collet M
FAU - Drouard, Christine
AU  - Drouard C
FAU - Lombard, Christophe
AU  - Lombard C
FAU - Herve, Daniel
AU  - Herve D
FAU - Strehlau, Gunther
AU  - Strehlau G
LA  - eng
PT  - Journal Article
PL  - Netherlands
TA  - J Vet Cardiol
JT  - Journal of veterinary cardiology : the official journal of the European Society 
      of Veterinary Cardiology
JID - 101163270
EDAT- 2004/05/01 00:00
MHDA- 2004/05/01 00:01
CRDT- 2008/12/17 09:00
PHST- 2008/12/17 09:00 [entrez]
PHST- 2004/05/01 00:00 [pubmed]
PHST- 2004/05/01 00:01 [medline]
AID - S1760-2734(06)70059-5 [pii]
AID - 10.1016/S1760-2734(06)70059-5 [doi]
PST - ppublish
SO  - J Vet Cardiol. 2004 May;6(1):7-13. doi: 10.1016/S1760-2734(06)70059-5.